Literature DB >> 21922354

Surgical management of pancreatic neuroendocrine tumors.

Wataru Kimura1, Koji Tezuka, Ichiro Hirai.   

Abstract

This study outlines the surgical management and clinicopathological findings of pancreatic neuroendocrine tumors (P-NETs). There are various surgical options, such as enucleation of the tumor, spleen-preserving distal pancreatectomy, distal pancreatectomy with splenectomy, pancreatoduodenectomy, and duodenum-preserving pancreas head resection. Lymph node dissection is performed for malignant cases. New guidelines and classifications have been proposed and are now being used in clinical practice. However, there are still no clear indications for organ-preserving pancreatic resection or lymph node dissection. Hepatectomy is the first choice for liver metastases of well-differentiated neuroendocrine carcinoma without extrahepatic metastases. On the other hand, cisplatin-based combination therapy is performed as first-line chemotherapy for metastatic poorly differentiated neuroendocrine carcinoma. Other treatment options are radiofrequency ablation, transarterial chemoembolization/embolization, and liver transplantation. Systematic chemotherapy and biotherapy, such as that with somatostatin analogue and interferon-α, are used for recurrence after surgery. The precise surgical techniques for enucleation of the tumor and spleen-preserving distal pancreatectomy are described.

Entities:  

Mesh:

Year:  2011        PMID: 21922354     DOI: 10.1007/s00595-011-4547-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  78 in total

1.  Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series.

Authors:  Riccardo Casadei; Claudio Ricci; Raffaele Pezzilli; Davide Campana; Paola Tomassetti; Lucia Calculli; Donatella Santini; Nicola Antonacci; Francesco Minni
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

2.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

3.  KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.

Authors:  Lizhi Zhang; Thomas C Smyrk; Andre M Oliveira; Christine M Lohse; Shuya Zhang; Michele R Johnson; Ricardo V Lloyd
Journal:  Am J Surg Pathol       Date:  2009-10       Impact factor: 6.394

4.  Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study.

Authors:  Lucio Gullo; Marina Migliori; Massimo Falconi; Paolo Pederzoli; Rossella Bettini; Riccardo Casadei; Gianfranco Delle Fave; Vito D Corleto; Claudio Ceccarelli; Donatella Santini; Paola Tomassetti
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

Review 5.  Surgical management of pancreatic endocrine tumors.

Authors:  Volker Fendrich; Jens Waldmann; Detlef K Bartsch; Peter Langer
Journal:  Nat Rev Clin Oncol       Date:  2009-06-09       Impact factor: 66.675

6.  Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.

Authors:  Karl Y Bilimoria; David J Bentrem; Ryan P Merkow; James S Tomlinson; Andrew K Stewart; Clifford Y Ko; Mark S Talamonti
Journal:  J Am Coll Surg       Date:  2007-08-03       Impact factor: 6.113

7.  Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.

Authors:  L Fischer; J Kleeff; I Esposito; U Hinz; A Zimmermann; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

8.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.

Authors:  A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10

9.  Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Authors:  Laureano Fernández-Cruz; Laia Blanco; Rebeca Cosa; Héctor Rendón
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  17 in total

1.  Combined associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) followed by left trisectionectomy and Whipple operation for PNET.

Authors:  Ren Ji; Shi Zuo; Siyuan Qiu; Ping Li; Albert Chan; William Sharr; Chung Mau Lo
Journal:  Gland Surg       Date:  2018-02

Review 2.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

3.  Outcome of surgery for ileojejunal neuroendocrine tumors.

Authors:  Nils Habbe; Volker Fendrich; Anna Heverhagen; Annette Ramaswamy; Detlef K Bartsch
Journal:  Surg Today       Date:  2012-11-11       Impact factor: 2.549

Review 4.  Pancreatic neuroendocrine tumor accompanied with multiple liver metastases.

Authors:  Tomohide Hori; Kyoichi Takaori; Shinji Uemoto
Journal:  World J Hepatol       Date:  2014-08-27

5.  Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.

Authors:  Javier A Cienfuegos; Joseba Salguero; Jorge M Núñez-Córdoba; Miguel Ruiz-Canela; Alberto Benito; Sira Ocaña; Gabriel Zozaya; Pablo Martí-Cruchaga; Fernando Pardo; José Luis Hernández-Lizoáin; Fernando Rotellar
Journal:  Surg Endosc       Date:  2017-01-26       Impact factor: 4.584

Review 6.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

Review 7.  Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1.

Authors:  Kazuhiro Hanazaki; Akihiro Sakurai; Masaya Munekage; Kengo Ichikawa; Tsutomu Namikawa; Takehiro Okabayashi; Masayuki Imamura
Journal:  Surg Today       Date:  2012-10-19       Impact factor: 2.549

8.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

Review 9.  Laparoscopic distal pancreatectomy: up-to-date and literature review.

Authors:  Maurizio Iacobone; Marilisa Citton; Donato Nitti
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

10.  Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.

Authors:  Masami Miki; Tetsuhide Ito; Masayuki Hijioka; Lingaku Lee; Kohei Yasunaga; Keijiro Ueda; Takashi Fujiyama; Yuichi Tachibana; Ken Kawabe; Robert T Jensen; Yoshihiro Ogawa
Journal:  Jpn J Clin Oncol       Date:  2017-06-01       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.